SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report)’s share price rose 11.1% during mid-day trading on Thursday . The stock traded as high as $7.19 and last traded at $7.2550. Approximately 8,457,704 shares traded hands during trading, an increase of 12% from the average daily volume of 7,522,891 shares. The stock had previously closed at $6.53.
Analyst Upgrades and Downgrades
SLS has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Tuesday, April 21st. Maxim Group lifted their price objective on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday, March 12th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $10.00.
View Our Latest Analysis on SELLAS Life Sciences Group
SELLAS Life Sciences Group Price Performance
SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the company. Quantinno Capital Management LP purchased a new position in SELLAS Life Sciences Group during the first quarter worth $315,000. Independent Financial Group LLC purchased a new position in SELLAS Life Sciences Group during the first quarter worth $98,000. Wealthfront Advisers LLC purchased a new position in SELLAS Life Sciences Group during the first quarter worth $48,000. Bank of New York Mellon Corp boosted its stake in SELLAS Life Sciences Group by 86.6% during the first quarter. Bank of New York Mellon Corp now owns 478,366 shares of the company’s stock worth $2,023,000 after buying an additional 221,957 shares during the period. Finally, Principal Financial Group Inc. purchased a new position in SELLAS Life Sciences Group during the first quarter worth $53,000. 17.38% of the stock is owned by hedge funds and other institutional investors.
About SELLAS Life Sciences Group
SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.
The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.
Read More
- Five stocks we like better than SELLAS Life Sciences Group
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
- MarketBeat Week in Review – 05/11 – 05/15
Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.
